1-7 of 7
Pierluigi Porcu
Close
Sort by
Journal Articles

The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T- and NK-cell lymphomas

Clinical Trials & Observations
Rahul S. Bhansali, Fredrik Ellin, Thomas Relander, Miao Cao, Wenrui Li, Qi Long, Nivetha Ganesan, Robert Stuver, Steven M. Horwitz, Kitsada Wudhikarn, Steven R. Hwang, N. Nora Bennani, Julio Chavez, Lubomir Sokol, Hayder Saeed, Frank Duan, Pierluigi Porcu, Priyanka Pullarkat, Neha Mehta-Shah, Jasmine M. Zain, Miguel Ruiz, Jonathan E. Brammer, Rishab Prakash, Swaminathan P. Iyer, Adam J. Olszewski, Ajay Major, Peter A. Riedell, Sonali M. Smith, Caroline Goldin, Bradley Haverkos, Bei Hu, Tony Z. Zhuang, Pamela B. Allen, Wael Toama, Murali Janakiram, Taylor R. Brooks, Deepa Jagadeesh, Nisha Hariharan, Aaron M. Goodman, Gabrielle Hartman, Paola Ghione, Fatima Fayyaz, Joanna M. Rhodes, Elise A. Chong, James N. Gerson, Daniel J. Landsburg, Sunita D. Nasta, Stephen J. Schuster, Jakub Svoboda, Mats Jerkeman, Stefan K. Barta
Journal: Blood Advances
Blood Adv (2024) 8 (13): 3507–3518.
https://doi.org/10.1182/bloodadvances.2024012800
Published: 2024
Includes: Supplemental data
Journal Articles

Frontline chemoimmunotherapy with nivolumab and dose-adjusted EPOCH in peripheral T-cell lymphoma: a phase 1 trial

Clinical Trials & Observations
Bradley Haverkos, Jasmine Zain, Manali Kamdar, Alexander Neuwelt, Eduardo Davila, Xander Bradeen, Ajay Major, Steven Bair, Jagar Jasem, Clayton Smith, Diana Abbott, Pierluigi Porcu
Journal: Blood Advances
Blood Adv (2024) 8 (3): 708–711.
https://doi.org/10.1182/bloodadvances.2023011526
Published: 2024
Journal Articles

Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b/2 study

Clinical Trials & Observations
Bradley Haverkos, Onder Alpdogan, Robert Baiocchi, Jonathan E. Brammer, Tatyana A. Feldman, Marcelo Capra, Elizabeth A. Brem, Santosh Nair, Phillip Scheinberg, Juliana Pereira, Leyla Shune, Erel Joffe, Patricia Young, Susan Spruill, Afton Katkov, Robert McRae, Ivor Royston, Douglas V. Faller, Lisa Rojkjaer, Pierluigi Porcu
Journal: Blood Advances
Blood Adv (2023) 7 (20): 6339–6350.
https://doi.org/10.1182/bloodadvances.2023010330
Published: 2023
Includes: Supplemental data
Journal Articles

The overlap of skin and blood T-cell clones in early-stage mycosis fungoides

Clinical Trials & Observations
Daniel Joffe, Safiyyah Bhatti, Lauren Banner, Romsin Zaya, Laura Gleason, Anjali Mishra, Ilan Kirsch, Pierluigi Porcu, Neda Nikbakht
Journal: Blood Advances
Blood Adv (2023) 7 (20): 6206–6210.
https://doi.org/10.1182/bloodadvances.2023010867
Published: 2023
Includes: Supplemental data
Journal Articles

Preclinical evaluation of anti-CD38 therapy in mature T-cell neoplasms

Colleen Isabelle, William T. Johnson, Kathleen McConnell, Ashley Vogel, Jonathan E. Brammer, Amy Boles, Robyn Keller, Paola Sindaco, Liam Nisenfeld, Guldeep Uppal, Neda Nikbakht, Bruno Calabretta, Patrizia Porazzi, Jerald Gong, Nitin Chakravarti, Pierluigi Porcu, Anjali Mishra
Journal: Blood Advances
Blood Adv (2023) 7 (14): 3637–3641.
https://doi.org/10.1182/bloodadvances.2023009807
Published: 2023
Includes: Supplemental data
Journal Articles

Highly cytotoxic natural killer cells are associated with poor prognosis in patients with cutaneous T-cell lymphoma

Bethany Mundy-Bosse, Nathan Denlinger, Eric McLaughlin, Nitin Chakravarti, Susan Hwang, Li Chen, Hsiaoyin Charlene Mao, David Kline, Youssef Youssef, Rebecca Kohnken, Dean Anthony Lee, Gerard Lozanski, Aharon G. Freud, Pierluigi Porcu, Basem William, Michael A. Caligiuri, Anjali Mishra
Journal: Blood Advances
Blood Adv (2018) 2 (15): 1818–1827.
https://doi.org/10.1182/bloodadvances.2018020388
Published: 2018
Includes: Supplemental data
Journal Articles

Pilot trial of ibrutinib in patients with relapsed or refractory T-cell lymphoma

Clinical Trials & Observations
Anita Kumar, Santosha Vardhana, Alison J. Moskowitz, Pierluigi Porcu, Ahmet Dogan, Jason A. Dubovsky, Matthew J. Matasar, Zhigang Zhang, Anas Younes, Steven M. Horwitz
Journal: Blood Advances
Blood Adv (2018) 2 (8): 871–876.
https://doi.org/10.1182/bloodadvances.2017011916
Published: 2018
Includes: Supplemental data